SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Zeifman RJ, Singhal N, dos Santos RG, Sanches RF, de Lima Osório F, Hallak JEC, Weissman CR. Psychopharmacology 2021; 238(2): 453-459.

Copyright

(Copyright © 2021, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s00213-020-05692-9

PMID

33118052

Abstract

RATIONALE: Suicidality is a major public health concern with limited treatment options. Accordingly, there is a need for innovative interventions for suicidality. Preliminary evidence indicates that treatment with the psychedelic ayahuasca may lead to decreases in depressive symptoms among individuals with major depressive disorder (MDD). However, there remains limited understanding of whether ayahuasca also leads to reductions in suicidality.
OBJECTIVE: To examine the acute and post-acute effect of ayahuasca on suicidality among individuals with MDD.
METHODS: We conducted a secondary analysis of an open-label trial in which individuals with recurrent MDD received a single dose of ayahuasca (N = 17). Suicidality was assessed at baseline; during the intervention; and 1, 7, 14, and 21 days after the intervention.
RESULTS: Among individuals with suicidality at baseline (n = 15), there were significant acute (i.e., 40, 80, 140, and 180 min after administration) and post-acute (1, 7, 14, and 21 days after administration) decreases in suicidality following administration of ayahuasca. Post-acute effect sizes for decreases in suicidality were large (Hedges' g = 1.31-1.75), with the largest effect size 21 days after the intervention (g = 1.75).
CONCLUSIONS: When administered in the appropriate context, ayahuasca may lead to rapid and sustained reductions in suicidality among individuals with MDD. Randomized, double-blind studies with larger sample sizes are needed to confirm this early finding.


Language: en

Keywords

Adult; Ayahuasca; Banisteriopsis; Depressive Disorder, Major; Drug Administration Schedule; Female; Hallucinogens; Humans; Intervention; Major depressive disorder; Male; Psychiatric Status Rating Scales; Recurrence; Suicidality; Suicide, Attempted; Time Factors

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print